HIV drug showdown: which regimen keeps the virus in check?
NCT ID NCT06393387
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked back at medical records of 800 people with HIV to compare two drug combinations: a two-drug regimen (DTG/3TC) and a three-drug regimen (BIC/F/TAF). The goal was to see how well each kept the virus suppressed over 48 weeks. Participants were adults already on HIV treatment, and the study focused on real-world effectiveness across multiple clinics in the Southeast US.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Midway Specialty Care Center
West Palm Beach, Florida, 33401, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia